Clinical Trial Update: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II trial evaluating nanoliposomal irinotecan (nal-IRI) in combination with nivolumab as second-line therapy for advanced biliary tract cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Nanoliposomal irinotecan (Nal-IRI) (irinotecan liposome)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Biliary Tract Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-02-13